Mesenchymal stem cell therapy for pulmonary hypertension: an update

Area of Science:

• Regenerative Medicine
• Cardiovascular Research
• Pulmonology

Background:

• Pulmonary Hypertension (PH) is a severe condition causing pulmonary vascular remodeling and right heart failure.
• Current treatments for PH have limited efficacy, highlighting the need for novel therapeutic strategies.
• Stem cell therapy, particularly mesenchymal stem cells (MSCs), offers potential for treating refractory diseases like PH.

Purpose of the Study:

• To review preclinical evidence of mesenchymal stem cell (MSC) therapy for pulmonary hypertension (PH).
• To explore the mechanisms by which MSCs exert therapeutic effects in PH models.
• To discuss the role of MSC-derived exosomes and future clinical applications of MSCs in PH treatment.

Main Methods:

• Review of preclinical studies investigating MSC therapy in PH models.
• Analysis of MSC effects on right ventricular function, pulmonary arterial smooth muscle cell proliferation, endothelial function, and inflammation.
• Examination of MSC-derived exosome efficacy and challenges in clinical translation.

Main Results:

• Preclinical studies demonstrate MSCs can alleviate right ventricular failure in PH.
• MSCs show potential to reverse pulmonary arterial smooth muscle cell proliferation and restore endothelial function.
• MSC therapy influences anti-inflammatory factor expression, contributing to therapeutic benefits.

Conclusions:

• Mesenchymal stem cell therapy holds significant promise as a treatment for pulmonary hypertension based on preclinical data.
• Further research is essential to elucidate the precise mechanisms of MSC action in PH.
• Development of strategies for safe and efficient large-scale MSC production is crucial for clinical application in PH.